Skip to Content

Megestrol Disease Interactions

There are 5 disease interactions with megestrol:

Major

Progestogens (Includes megestrol) ↔ thromboembolism

Severe Potential Hazard, High plausibility. Applies to: History - Thrombotic/Thromboembolic Disorder, Thrombotic/Thromboembolic Disorder, Cerebral Vascular Disorder

The use of progestogens, in general, is considered by manufacturers to be contraindicated in patients with active thrombophlebitis, cerebrovascular disease, or a current or past history of thromboembolic disorders. While the role of progestogens in the development of thromboembolic events associated with hormonal therapy is often unclear and thought to be secondary to that of estrogens, it may not be insignificant. Medroxyprogesterone, a common progestational agent, has been shown to produce a hypercoagulable state in high dosages. Whether or not this effect contributes to the development of thrombotic events is unknown. However, thrombophlebitis and pulmonary embolism have been reported with megestrol, an antineoplastic and progestational agent. In addition, an increased risk of nonfatal venous thrombosis has been associated with oral contraceptive combinations containing desogestrel or gestodene relative to those that contain other progestins (e.g., levonorgestrel, norethindrone), suggesting some degree of hemostatic effect by progestogens.

References

  1. "Product Information. Depo-Provera (medroxyprogesterone)." Pharmacia and Upjohn, Kalamazoo, MI.
  2. "Product Information. Ortho-Cept (desogestrel-ethinyl estradiol)." Ortho Pharmaceutical Corporation, Raritan, NJ.
  3. "Product Information. Provera (medroxyprogesterone)." Pharmacia and Upjohn, Kalamazoo, MI.
  4. "Product Information. Megace (megestrol)." Bristol-Myers Squibb, Princeton, NJ.
  5. "Product Information. Ortho-Cyclen (ethinyl estradiol-norgestimate)." Ortho Pharmaceutical Corporation, Raritan, NJ.
  6. "Product Information. Norplant System (levonorgestrel)" Wyeth-Ayerst Laboratories, Philadelphia, PA.
  7. "Product Information. Lo/Ovral (ethinyl estradiol-norgestrel)." Wyeth-Ayerst Laboratories, Philadelphia, PA.
  8. "Product Information. Micronor (norethindrone)" Ortho McNeil Pharmaceutical, Raritan, NJ.
  9. Fukutomi T, Nanasawa T, Yamamoto H, Adachi I, Watanabe T "The induction of a hypercoagulable state by medroxyprogesterone acetate in breast cancer patients." Jpn J Surg 20 (1990): 665-70
  10. "Product Information. Demulen (ethinyl estradiol-ethynodiol)." Searle, Skokie, IL.
  11. Yamamoto H, Noguchi S, Miyauchi K, Inaji H, Imaoka S, Koyama H, Iwanaga T "Changes in hematologic parameters during treatment with medroxyprogesterone acetate for breast cancer." Jpn J Cancer Res 82 (1991): 420-5
  12. "Product Information. Ovrette (norgestrel)" Wyeth-Ayerst Laboratories, Philadelphia, PA.
  13. Astedt B, Jeppsson S, Pandolfi M "Fibrinolytic activity of veins during use of depot medroxyprogesterone acetate as a contraceptive." Fertil Steril 23 (1972): 489-92
  14. "Product Information. Triphasil (ethinyl estradiol-levonorgestrel)." Wyeth-Ayerst Laboratories, Philadelphia, PA.
  15. "Product Information. Ortho Novum 10/11 (ethinyl estradiol-norethindrone)." Ortho Pharmaceutical Corporation, Raritan, NJ.
View all 15 references
Moderate

Estrogens/progestogens (Includes megestrol) ↔ fluid retention

Moderate Potential Hazard, Moderate plausibility. Applies to: Congestive Heart Failure, Migraine, Seizures, Renal Dysfunction, Fluid Retention, Hypertension

Estrogens and progestogens may cause fluid retention, particularly when given in high dosages or for prolonged periods. Therapy with these agents should be administered cautiously in patients who have preexisting problems with excess fluid. In addition, patients with conditions that may be adversely affected by fluid accumulation, such as asthma, epilepsy, migraine, and cardiovascular or renal dysfunction, should be observed for exacerbation of their condition during estrogen and/or progestogen therapy.

References

  1. "Product Information. Estrace (estradiol)." Warner Chilcott Laboratories, Rockaway, NJ.
  2. "Product Information. Demulen (ethinyl estradiol-ethynodiol)." Searle, Skokie, IL.
  3. "Product Information. Micronor (norethindrone)" Ortho McNeil Pharmaceutical, Raritan, NJ.
  4. "Product Information. Provera (medroxyprogesterone)." Pharmacia and Upjohn, Kalamazoo, MI.
  5. "Product Information. Depo-Provera (medroxyprogesterone)." Pharmacia and Upjohn, Kalamazoo, MI.
  6. "Product Information. Ortho-Cyclen (ethinyl estradiol-norgestimate)." Ortho Pharmaceutical Corporation, Raritan, NJ.
  7. "Product Information. Ortho-Cept (desogestrel-ethinyl estradiol)." Ortho Pharmaceutical Corporation, Raritan, NJ.
  8. "Product Information. Norplant System (levonorgestrel)" Wyeth-Ayerst Laboratories, Philadelphia, PA.
  9. "Product Information. Megace (megestrol)." Bristol-Myers Squibb, Princeton, NJ.
  10. "Product Information. Triphasil (ethinyl estradiol-levonorgestrel)." Wyeth-Ayerst Laboratories, Philadelphia, PA.
  11. "Product Information. Ovrette (norgestrel)" Wyeth-Ayerst Laboratories, Philadelphia, PA.
  12. "Product Information. Ortho Novum 10/11 (ethinyl estradiol-norethindrone)." Ortho Pharmaceutical Corporation, Raritan, NJ.
  13. "Product Information. Ortho Novum 1/50 (mestranol-norethindrone)." Ortho Pharmaceutical Corporation, Raritan, NJ.
  14. "Product Information. Emcyt (estramustine)." Pharmacia and Upjohn, Kalamazoo, MI.
  15. "Product Information. Premarin (conjugated estrogens)." Wyeth-Ayerst Laboratories, Philadelphia, PA.
  16. "Product Information. Ogen (estropipate topical)" Pharmacia and Upjohn, Kalamazoo, MI.
  17. "Product Information. Climara (estradiol)." Berlex, Richmond, CA.
  18. "Product Information. Vivelle (estradiol)." Ciba Pharmaceuticals, Summit, NJ.
  19. "Product Information. Ortho-Est (estropipate)." Ortho McNeil Pharmaceutical, Raritan, NJ.
  20. "Product Information. Lo/Ovral (ethinyl estradiol-norgestrel)." Wyeth-Ayerst Laboratories, Philadelphia, PA.
  21. "Product Information. Estinyl Tablets (ethinyl estradiol)" Schering Corporation, Kenilworth, NJ.
  22. "Product Information. Estratab (esterified estrogens)" Solvay Pharmaceuticals Inc, Marietta, GA.
  23. "Product Information. Estraderm (estradiol)." Ciba Pharmaceuticals, Summit, NJ.
  24. Leiman G "Depo-medroxyprogesterone acetate as a contraceptive agent: its effect on weight and blood pressure." Am J Obstet Gynecol 114 (1972): 97-102
  25. "Product Information. Ortho Dienestrol Cream (dienestrol topical)" Ortho McNeil Pharmaceutical, Raritan, NJ.
View all 25 references
Moderate

Estrogens/progestogens (Includes megestrol) ↔ retinal thrombosis

Moderate Potential Hazard, Moderate plausibility. Applies to: Visual Defect/Disturbance

Estrogens and progestogens may cause retinal thrombosis. Oral contraceptives should be discontinued if there is unexplained partial or complete loss of vision; onset of proptosis or diplopia; papilledema; or retinal vascular lesions. Therapy with these agents should be administered cautiously in patients who have preexisting ocular problems and appropriate diagnostic and therapeutic measures should be instituted. Contact lens wearers who develop visual changes or changes in lens tolerance should be assessed by an ophthalmologist.

Moderate

Megestrol (Includes megestrol) ↔ diabetes mellitus

Moderate Potential Hazard, High plausibility. Applies to: Diabetes Mellitus

Megestrol, like other progestational agents, can cause glucose intolerance. In addition, it may have glucocorticoid activity. New onset diabetes and exacerbation of preexisting diabetes have been reported in association with the chronic use of megestrol. Patients with diabetes mellitus should be monitored more closely during therapy with megestrol, and adjustments made accordingly in their antidiabetic regimen.

References

  1. Hardy H, Esch LD, Morse GD "Glucose disorders associated with HIV and its drug therapy." Ann Pharmacother 35 (2001): 343-51
  2. Henry K, Rathgaber S, Sullivan C, McCabe K "Diabetes mellitus induced by megestrol acetate in a patient with AIDS and cachexia." Ann Intern Med 116 (1992): 53-4
  3. Kilby JM, Tabereaux PB "Severe hyperglycemia in an HIV clinic: preexisting versus drug- associated diabetes mellitus." J Acquir Immune Defic Syndr Hum Retrovirol 17 (1998): 46-50
  4. Leinung MC, Liporace R, Miller CH "Induction of adrenal suppression by megestrol acetate in patients with AIDS." Ann Intern Med 122 (1995): 843-5
  5. "Product Information. Megace (megestrol)." Bristol-Myers Squibb, Princeton, NJ.
View all 5 references
Moderate

Megestrol (Includes megestrol) ↔ hyperadrenocorticalism

Moderate Potential Hazard, High plausibility. Applies to: Adrenal Tumor, Hyperadrenocorticism

Megestrol appears to have glucocorticoid activity and may aggravate conditions of hyperadrenocorticalism. Clinical cases of overt Cushing's syndrome and adrenal insufficiency have been reported in association with the chronic use of megestrol.

References

  1. Leinung MC, Liporace R, Miller CH "Induction of adrenal suppression by megestrol acetate in patients with AIDS." Ann Intern Med 122 (1995): 843-5
  2. "Product Information. Megace (megestrol)." Bristol-Myers Squibb, Princeton, NJ.
  3. Caparros GC, Zambrana JL, Delgado-Fernandez M, Diez F "Megestrol-induced Cushing syndrome." Ann Pharmacother 35 (2001): 1208-10
  4. Koch CA, Pacak K "Abnormal ACTH-stimulation test in a patient with AIDS: adrenal insufficiency or toxoplasmosis?" Endocr Regul 35 (2001): 91-3
View all 4 references

Megestrol drug interactions

There are 175 drug interactions with megestrol

Megestrol alcohol/food interactions

There is 1 alcohol/food interaction with megestrol

Drug Interaction Classification

The classifications below are a general guideline only. It is difficult to determine the relevance of a particular drug interaction to any individual given the large number of variables.
Major Highly clinically significant. Avoid combinations; the risk of the interaction outweighs the benefit.
Moderate Moderately clinically significant. Usually avoid combinations; use it only under special circumstances.
Minor Minimally clinically significant. Minimize risk; assess risk and consider an alternative drug, take steps to circumvent the interaction risk and/or institute a monitoring plan.
Unknown No information available.

Do not stop taking any medications without consulting your healthcare provider.

Further information

Always consult your healthcare provider to ensure the information displayed on this page applies to your personal circumstances.

Hide